악성 협착증의 담관 배액을 위한 Hot AXIOS™ (RAINBOW)
악성 담도 협착증(RAINBOW) 환자의 내시경 초음파 유도 담도 배액에 관한 프랑스 전향적 연구
The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring drainage of the bile ducts after failure of ERCP, in the two months after stent placement.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The study will evaluate the quality of life in patients with malignant biliary obstruction after the placement of a lumen-apposing metal stent via endoscopic ultrasound, with an emphasis on the improvement of quality of life measured as a reduction in jaundice. Improvement in jaundice is a direct indicator of effective bile drainage and is expected to correlate with an enhancement in overall quality of life. Quality of life will be measured by means of subject response to the EORTC QLQ-BIL21, a component of the European Organization for Research and Treatment of Cancer (EORTC) designed specifically to assess the quality of life in patients with biliary tract cancer. The QLQ-BIL21 consists of 21 questions which aim to evaluate specific symptoms and issues relevant to patients with biliary tract cancer, such as jaundice, pain, digestive problems and the psychosocial impact of the disease.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Besançon, 프랑스, 25030
- CHU de Besançon
-
Cornebarrieu, 프랑스, 31700
- Clinique des Cedres, Ramsay Sante
-
Limoges, 프랑스, 87042
- CHU Limoges
-
Lyon, 프랑스, 69008
- Hopital Prive Jean Mermoz
-
Nantes, 프랑스, 44300
- Clinique Jules Verne
-
Nice, 프랑스, 06202
- CHU Nice
-
Paris, 프랑스, 75012
- Hopital Saint Antoine
-
Paris, 프랑스, 75908
- Hopital Europeen Georges-Pompidou
-
Paris, 프랑스, 75014
- Hopital Paris Saint-Joseph
-
Poitiers, 프랑스, 86021
- CHU de Poitiers
-
Reims, 프랑스, 51092
- CHU Reims
-
Rennes, 프랑스, 35033
- CHRU Hopital Pontchaillou
-
Rouen, 프랑스, 76000
- Clinique Saint-Hilaire
-
Saint-Herblain, 프랑스, 44800
- Santé Atlantique
-
Strasbourg, 프랑스, 67091
- CHU de Strasbourg
-
Toulouse, 프랑스, 31059
- CHU Rangueil
-
Vandœuvre-lès-Nancy, 프랑스, 54500
- CHRU de Nancy
-
Vichy, 프랑스, 03200
- Centre Hospitalier de Vichy
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients 18 years or older
- Willing and able to comply with study procedures and provide written informed consent
- Patients with failed ERCP for treatment of suspected malignant biliary obstruction
- Patients for whom an indication for Hot AXIOS™ stent placement has been determined
Exclusion Criteria:
- Women who are pregnant, nursing or planning to become pregnant during the study
- Patients with immediately resectable tumor or resectable during the two months of the study
- Patients for whom the placement of a double pigtail prosthesis is planned by the investigator during the index procedure
- Current participation in another investigation drug or device study that could interfere with the endpoints of this study
- Persons under guardianship or curatorship
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Hot AXIOS™ Recipients
The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study. |
The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality of Life Measurement - Jaundice Dimension
기간: 2 months (± 15 days)
|
The primary outcome is the difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the jaundice dimension consists of three of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality of Life Measurement - Non-Jaundice Dimension
기간: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the non-jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the non-jaundice dimension consists of 18 of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Quality of Life Measurement - Global Score
기간: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the global score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much). A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Reduction in Bilirubin (Clinical Success)
기간: 2 weeks (+ 7 days) and 2 months (± 15 days)
|
Clinical success is defined as a reduction in bilirubin > 50% at each follow-up compared to baseline. |
2 weeks (+ 7 days) and 2 months (± 15 days)
|
|
Rate of Resolution of Clinical Symptoms
기간: 2 months (± 15 days)
|
Resolution of GOO-related clinical symptoms such as jaundice, nausea/vomiting, fever/chills, weight loss and abdominal pain following implant of Hot AXIOS™ at 2 months of follow-up |
2 months (± 15 days)
|
|
Rate of Reintervention
기간: 2 months (± 15 days)
|
Reintervention is defined as endoscopic, radiological or surgical intervention for the management of recurrent biliary obstruction due to stent dysfunction (e.g., obstruction or migration) at 2 months of follow-up. This criterion will be measured within the population for whom the placement of the Hot AXIOS™ stent was a technical success. |
2 months (± 15 days)
|
|
Chemotherapy Status
기간: 2 months (± 15 days)
|
Number of days after study stent implantation to start or continuation of chemotherapy (if applicable). |
2 months (± 15 days)
|
|
Overall Survival
기간: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the date of death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure overall survival. |
2 months (± 15 days)
|
|
Progression-Free Survival
기간: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the earliest date of either disease progression or death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure progression-free survival. |
2 months (± 15 days)
|
|
Number of Days Alive after Hospital Discharge
기간: 2 months (± 15 days)
|
Number of days alive after hospital discharge within 2 months after the placement of the Hot AXIOS™. |
2 months (± 15 days)
|
|
Rate of Technical Success
기간: 2 months (± 15 days)
|
Technical success is defined as the successful placement of the Hot AXIOS™ stent during study procedure. |
2 months (± 15 days)
|
|
Serious Adverse Events
기간: 2 months (± 15 days)
|
Serious adverse events related to the study procedure and/or the Hot AXIOS™ stent. |
2 months (± 15 days)
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Jean-Baptiste Chevaux, Central Hospital, Nancy, France
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- E7209
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .